Fennec Swings to Q3 Profit, Sales Rise 56%
Fennec Pharmaceuticals reported a strong third quarter of 2026, with revenue rising 57% to $19.6 million as PEDMARK sales grew 56% to $19.4 million, marking the company’s eighth consecutive quarter of growth. The company swung to net income of $4.64 million, or $0.12 per share, compared with a year-earlier loss, and adjusted EBITDA increased to $5.8 million; earnings and revenue also topped analyst estimates. Management cited rising demand, record infusions and increased enrollment in its patient-support program, alongside broader adoption among community oncologists and continued commercial expansion. Higher selling and marketing costs accompanied the expanded sales organization, while Fennec reported $48.7 million in cash and positive operating cash flow of $6.7 million.





